Table 1.

Data from clinical trials of the new therapies for multiple sclerosis (MS).

Drug	Trial	Dose	% reduction in annualized relapse rate	% reduction in disease progression			MRI signs			Measure of tissue damage or loss
				At 3 months	At 6 months	At 2 years	% reduction in gadolinium enhancing lesions per T1 scan	% reduction in new lesion on T2 at 2 years	New T1 lesions	% reduction in volume of lesions on T1	% reduction in volume of lesions on T2	Brain loss reduction at 2 years
Fingolimod	FREEDOMS	0.5 mg	54.0*	27.6*	34.2*	NA	81.0*	74.0*	NA	82.6*	68.6*	35.9*
	(Kappos et al., 2010)	1.25 mg	60.0*	31.1*	39.4	NA	81.0*	74.0*	NA	75.9*	95.2*	32.0*
Teriflunomide	TEMSO	7 mg	31.5*	20.5	NA	NA	57.1*	NA	NA	5.7	51.5*	25.0
	(O’Connor et al., 2011)	14 mg	31.5*	26.0*	NA	NA	80.5*	NA	NA	37.7*	76.7*	25.0
Teriflunomide	TOWERS	7 mg	22.0*	NA	NA	−7.1	NA	NA	NA	NA	NA	NA
	(Confavreux et al., 2014)	14 mg	36.0*	NA	NA	19.8*	NA	NA	NA	NA	NA	NA
Dimethyl fumarate	DEFINE	240 mg BD	52.7*	NA	NA	40.7*	94.4*	84.7*	NA	NA	NA	NA
	(Gold et al., 2012a)	240 mg TDS	47.2*	NA	NA	33.3*	72.2*	74.1	NA	NA	NA	NA
Dimethyl fumarate	CONFIRM	240 mg BD	45.0*	NA	NA	23.5	75.0*	70.7*	57.1*	NA	NA	NA
	(Fox et al., 2012)	240 mg TDS	50.0*	NA	NA	23.5	80.0*	73.0*	65.7*	NA	NA	NA
Laquinimod	ALLEGRO	0.6 mg	23.0*	NA	NA	29.3*	37.3*	29.6*	NA	NA	NA	33.1*
	(Comi et al., 2012)
Laquinimod	BRAVO	0.6 mg	17.6	23.1	30.0*	NA	21.4	16.5	NA	NA	NA	27.2*
	(Vollmer et al., 2014)

Data from seven clinical trials was extracted and % reductions in clinical indicators and MRI indicators compared to placebo were calculated and presented in the above table. *p < 0.05.